TDO2 and cancer: While there are currently no approved drugs that function as IDO modulators, candidates, such as epacadostat, indoximod, and GDC-0919, are in various phases of clinical trials, and the identification of novel IDO1 and TDO inhibitors remains of interest in anticancer drug discovery (see Reference [149] for a review of IDO in cancer and cancer therapy).